Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus methotrexate in recurrent or metastatic head and neck squamous cell carcinoma after platinum therapy
2011-001938-42Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Nov 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Cabazitaxel with Methotrexate (2 arms). Primary endpoint: Progression-free survival rate at 18 weeks. Started Nov 2011; status: completed.
02
Drugs
cabazitaxelmethotrexate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2011-001938-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001938-42.